Europe must rethink medicine pricing or risk losing investments, pharma lobby chief says

Sanofi SA

23/06/2026 13:16

BRUSSELS, June 23 (Reuters) - Europe will need to rethink how it values and pays for innovative medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said on Tuesday, as governments and drugmakers clash over prices. 
Stefan Oelrich, president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), said in an interview that the industry faced a new reality as U.S. President Donald Trump's "most-favoured nation" pricing policy seeks to tie some U.S. medicine prices to those paid in other wealthy countries, including in Europe. 

 (Reporting by Maggie Fick in Brussels. Editing by Mark Potter)
 ((maggie.fick@thomsonreuters.com; +44 7890 916706;))